Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis
Donald R. VanDevanter(Case Western Reserve University), Patrick A. Flume(Medical University of South Carolina), Cori Daines, Christopher H. Goss(University of Washington Medical Center), Ronald L. Gibson(Seattle Children's Hospital), Jonathan E. Spahr(Children's Hospital of Pittsburgh), Raksha Jain(Westmead Institute for Medical Research), Valeria Beckett(Cystic Fibrosis Foundation), Don B. Sanders(Indiana University School of Medicine), Elliott C. Dasenbrook(Cleveland Clinic), Sonya L. Heltshe
Cited by 53
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Efficacy of Aerosolized Tobramycin in Patients with Cystic Fibrosis
|New England Journal of Medicine|1993|458
Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections
|American Journal of Respiratory and Critical Care Medicine|2017|393